Pfizer: FY24 guidance includes ~$10.5B in revenue from Comirnaty, Paxlovid
The Fly

Pfizer: FY24 guidance includes ~$10.5B in revenue from Comirnaty, Paxlovid

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenues; and this growth guidance takes into consideration the reduction of sales associated with the previously announced global withdrawal of Oxbryta.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App